HCW Biologics Inc. Proceeds from Long-Term Debt Issued
HCW Biologics Inc. (HCWB) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2022-03-29
- HCW Biologics Inc. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- HCW Biologics Inc. proceeds from issuance of long-term debt for fiscal 2020 was $563.59K.
| Period end | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-29 |
| 2020-12-31 | $563.59K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |